TOI_OUT_1 [2025-04-02 11:41:02 -0400] 3280 Bytes | 907 tokens | Cum: 907 tkns (11.34% of 8k)
==========================================================================

Booyah, my friends! It's already 11:41:00 AM on Wed Apr 02, 2025 -0400, and I've got my eyes locked on The Oncology Institute (TOI), pushing up to 1.48 from 1.26. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: The Oncology Institute (TOI)
IPO: 2021-11-15 (3 Years Ago)
Market Cap: $110,577,271
Shares Outstanding: 75,750,000
Industry: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE
Exchange: XNAS
Description: The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

Here's the first list of news for The Oncology Institute:

C1 - Apr-01-25 10:04AM - The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025
C2 - Mar-31-25 08:00AM - TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1
C3 - Mar-26-25 03:02AM - The Oncology Institute Inc (TOI) Q4 2024 Earnings Call Highlights: Navigating Growth Amidst ...
C4 - Mar-25-25 06:28PM - The Oncology Institute, Inc. (TOI) Q4 2024 Earnings Call Transcript
C5 - Mar-24-25 09:05AM - Earnings To Watch: The Oncology Institute Inc (TOI) Reports Q4 2024 Result
C6 - Mar-24-25 09:05AM 06:01AM - The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
C7 - Mar-24-25 09:05AM 06:00AM - The Oncology Institute Announces $16.5 million Private Placement
C8 - Mar-04-25 08:00AM - The Oncology Institute Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

Prior AI Reports for TOI:
1. 2025-04-01 – Score: 70 – Target: 1.8900 – Highs: – / – / –
oncology-institute-sees-strong-growth-amidst-concerns-over-high-debt-and-negative-returns
2. 2025-03-24 – Score: 85 – Target: 1.6100 – Highs: 1.3600 / 1.4286 / 1.30
strong-performance-and-sales-growth-propel-oncology-institutes-upward-trend

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on The Oncology Institute (TOI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TOI_OUT_3 [2025-04-02 11:41:14 -0400] 1098 Bytes | 377 tokens | Cum: 1286 tkns (16.07% of 8k)
==========================================================================

Showing C3 (chunk 1 of 6): C3:
**The Oncology Institute Inc (TOI) Q4 2024 Earnings Call Highlights: Navigating Growth Amidst ...**
Date: Mar-26-25 03:02AM
Source: (GuruFocus.com)
URL: https://finance.yahoo.com/news/oncology-institute-inc-toi-q4-070245969.html

Revenue:Q4 2024 revenue was $100.3 million, a 17% increase from Q4 2023. Full year 2024 revenue was $393 million, up 21.3% from 2023.

Gross Profit:Q4 2024 gross profit was $14.6 million, a 2% increase from Q4 2023. Full year 2024 gross profit was $54 million, a 9.4% decrease from 2023.

SG&A Expenses:Q4 2024 SG&A decreased by 12% compared to Q4 2023. Full year 2024 SG&A was $114 million, a $5.6 million decrease from 2023.

Net Loss:Q4 2024 net loss was $13 million, an improvement of $5.6 million compared to Q4 2023. Full year 2024 net loss was $64.6 million, a decrease of $18.4 million from 2023.

Adjusted EBITDA:Q4 2024 adjusted EBITDA was negative $7.8 mi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TOI_OUT_5 [2025-04-02 11:41:15 -0400] 982 Bytes | 293 tokens | Cum: 1828 tkns (22.85% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T14:04:41Z - The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025...
A2 - 2025-03-31T13:02:14Z - Friday's Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy By Investing.com...
A3 - 2025-03-31T13:02:13Z - Friday's Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy By Investing.com...
A4 - 2025-03-31T13:02:14Z - Friday's Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy By Investing.com...
A5 - 2025-03-29T23:20:27Z - Daniel Virnich Buys 22,640 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TOI_OUT_7 [2025-04-02 11:41:16 -0400] 1098 Bytes | 298 tokens | Cum: 2128 tkns (26.60% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025**Date: 2025-04-01Source: {'uri': 'finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://finance.yahoo.com/news/oncology-institute-inc-toi-among-140441442.htmlWe recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where The Oncology Institute, Inc. (NASDAQ:TOI) stands against other stocks insiders were buying in Q1 2025.

About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while the blue-chip companies gained 0.9%. Meanwhile, the Nasdaq Composite dropped 0.5%. Some stocks were recovering from Friday losses after inflation data came in higher than expected, coupled with weak consumer sentiment, which heightened concerns about the U.S. economy's stability, according to Investope

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TOI_OUT_9 [2025-04-02 11:41:16 -0400] 861 Bytes | 270 tokens | Cum: 2400 tkns (30.00% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-24T10:00:00Z - The Oncology Institute Announces $16.5 million Private Placement
B2 - 2024-11-21T12:00:00Z - Grapevine Saves The Oncology Institute Millions On Healthcare Supplies
B3 - 2024-11-05T00:09:00Z - The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call
B4 - 2024-09-30T12:00:00Z - The Oncology Institute of Hope & Innovation Launches Oregon Market
B5 - 2024-05-14T22:05:02Z - The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
B6 - 2024-05-09T12:10:06Z - Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TOI_OUT_11 [2025-04-02 11:41:21 -0400] 793 Bytes | 204 tokens | Cum: 2606 tkns (32.57% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**The Oncology Institute Announces $16.5 million Private Placement**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/24/3047652/0/en/The-Oncology-Institute-Announces-16-5-million-Private-Placement.htmlThe Oncology Institute, Inc. (TOI) announced a $16.5 million private placement with existing investors, management, and directors. The proceeds will be used for organic growth and working capital. The company also entered an exchange agreement with Deerfield Management Company to exchange convertible notes for preferred stock and warrants.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TOI_OUT_13 [2025-04-02 11:41:22 -0400] 537 Bytes | 148 tokens | Cum: 2827 tkns (35.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S10 - 2025-03-27 8-K Item1.01. Entry into a Material Definitive Agrmt.

On March 26, 2025, The Oncology Institute, Inc. (the Company) closed its previously announced private placement (the Private Placement) of an aggregate of: (i) 12,006,510 shares (the Shares) of the Companys common stock, pa...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TOI_OUT_15 [2025-04-02 11:41:26 -0400] 1099 Bytes | 289 tokens | Cum: 3118 tkns (38.98% of 8k)
==========================================================================

Showing S10 (chunk 1 of 4): S10:
Item1.01. Entry into a Material Definitive Agreement.

On March 26, 2025, The Oncology Institute, Inc. (the Company) closed its previously announced private placement (the Private Placement) of an aggregate of: (i) 12,006,510 shares (the Shares) of the Companys common stock, par value $0.0001 per share (the Common Stock), (ii) pre-funded warrants (the Pre-Funded Warrants) to purchase up to an aggregate of 2,886,614 shares of Common Stock and (iii) accompanying common warrants (the Common Warrants, together with the Pre-Funded Warrants, the Warrants) to purchase up to an aggregate of 7,446,562 shares of Common Stock (collectively, the Private Placement) to certain investors, including existing investors, as well as members of the Companys management team and board of directors, and entities affiliated with members of the Companys board of directors (the Purchasers). The Shares and W

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TOI_OUT_17 [2025-04-02 11:41:38 -0400] 17153 Bytes | 3949 tokens | Cum: 7172 tkns (89.65% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 769,218 | Perf Month: 115.59% | Option/Short: No / Yes | Sales Y/Y TTM: 21.33% |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 769.24K | Perf Quarter: 365.00% | Short Float: 2.99% | ROE: -174.88% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 3.03 | Index: - | Short Ratio: 1.44 | ROI: -44.16% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 76.08 | Market Cap: 112.72M | Short Interest: 1.10M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.18 | Shs Outstand: 75.74M | Beta: 0.23 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: 58.29% | Shs Float: 36.91M | Sales Q/Q: 16.88% | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: 66.68% | Inst Own: 14.99% | Sales past 5Y: 16.48% | Earnings: Mar 25 AMC |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: 207.91% | Insider Own: 51.27% | Employees: 825 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 22.98% | Insider Trans: 4.98% | Debt/Eq: 34.33 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Oncology Institute, Inc. (TOI) by Carter Robert Ross (Chief Financial Officer) on 2025-03-26
- Common Stock: 9056 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 4528 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Oncology Institute, Inc. (TOI) by BARASCH RICHARD A (Unknown Title) on 2025-03-26
- Common Stock: 1358448 shares at $1.0417 (I) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
- Common Warrant: 679224 shares at $0.125 (I) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").

Inside Trans: Oncology Institute, Inc. (TOI) by Hively Brad (Unknown Title) on 2025-03-26
- Common Stock: 9056 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 4528 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Oncology Institute, Inc. (TOI) by Virnich Daniel (Chief Executive Officer) on 2025-03-26
- Common Stock: 22640 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 11320 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Oncology Institute, Inc. (TOI) by Podnos Yale (Chief Medical Officer) on 2025-03-26
- Common Stock: 9056 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 4528 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Oncology Institute, Inc. (TOI) by Castle Jeremy (Chief Operating Officer) on 2025-03-26
- Common Stock: 9056 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 4528 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Oncology Institute, Inc. (TOI) by M33 Growth I L.P. (Unknown Title) on 2025-03-26
- Common Stock: 2716898 shares at $1.0417 (D)
- Warrant to Purchase Shares of Common Stock: 1358449 shares at $0.125 (D)

Inside Trans: Oncology Institute, Inc. (TOI) by Pacala Mark L (Unknown Title) on 2025-03-26
- Common Stock: 90562 shares at $1.0417 (I) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
- Common Warrant: 42281 shares at $0.125 (I) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").

Inside Trans: Oncology Institute, Inc. (TOI) by Johnson Karen Marie (Unknown Title) on 2025-03-26
- Common Stock: 36224 shares at $1.0417 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Common Warrant: 18112 shares at $0.125 (D) Footnote: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 393412000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -64663000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.5101
Average Volume: 598953.91
30-Day High: 1.5101
30-Day Low: 0.6149

[Detailed Financials: TTM 2024]
- Total Assets: $172,717,000.0
- Total Liabilities: $169,128,000.0
- Total Equity: $3,589,000.0
- Current Assets: $112,418,000.0
- Current Liabilities: $52,215,000.0

[Income Statement: TTM 2024]
- Revenue: $393,412,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.71

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $16,181,000.0

[Detailed Financials: FY 2024]
- Total Assets: $172,717,000.0
- Total Liabilities: $169,128,000.0
- Total Equity: $3,589,000.0
- Current Assets: $112,418,000.0
- Current Liabilities: $52,215,000.0

[Income Statement: FY 2024]
- Revenue: $393,412,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.71

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $16,181,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TOI_OUT_19 [2025-04-02 11:41:40 -0400] 676 Bytes | 167 tokens | Cum: 7621 tkns (95.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TOI_IN_21 [2025-04-02 11:41:40 -0400] 126 Bytes | 29 tokens | Cum: 7678 tkns (95.97% of 8k)
==========================================================================

====================================
[2025-04-02 11:41:40] # Analysis Completed
Elapsed Time: 40.39 seconds